Photochemical Internalization of Bleomycin Before External-Beam Radiotherapy Improves Locoregional Control in a Human Sarcoma Model

2009 ◽  
Vol 75 (3) ◽  
pp. 878-885 ◽  
Author(s):  
Ole-Jacob Norum ◽  
Øyvind Sverre Bruland ◽  
Ludmila Gorunova ◽  
Kristian Berg
2018 ◽  
Vol 52 (4) ◽  
pp. 453-460 ◽  
Author(s):  
Nikola Besic ◽  
Marta Dremelj ◽  
Gasper Pilko

Abstract Background Locoregional recurrence is common in patients with locally advanced differentiated thyroid carcinoma (DTC). Our aim was to find out the rate of locoregional control of the disease after external beam radiotherapy (EBRT) of the neck and mediastinum in patients with DTC and pT4 tumor. Patients and methods Altogether 91 patients (47 males, 44 females, median age 61 years) with DTC had EBRT of the neck and mediastinum as part of the multimodal treatment of pT4 tumor (63 cases pT4a, 28 cases pT4b) from the year 1973 to 2015. Data on clinical factors, histopathology and recurrence were collected. Disease-free, disease-specific and overall survival was calculated. Results Median tumor size was 5 cm (range 1–30 cm). Out of 91 patients, 23 had distant and 38 regional metastases. A total or near-total thyroidectomy, lobectomy, subtotal thyroidectomy and lymph node dissection was performed in 70%, 14%, 2% and 30% of cases, respectively. Thirteen percent of patients were not treated with surgery. All patients had EBRT and 39 had chemotherapy. Radioiodine (RAI) ablation of thyroid remnant and RAI therapy was applied in 90% and 40% of cases, respectively. Recurrence was diagnosed in 29/64 patients without a persistent disease: locoregional and distant in 16 and 13 cases, respectively. Five-year and ten-year disease-free survival rate was 64% and 48%, respectively. Conclusions The majority of patients with DTC and pT4 tumors who were treated with EBRT of the neck and mediastinum region as part of multimodal treatment have long-lasting locoregional control of the disease.


Head & Neck ◽  
2015 ◽  
Vol 38 (4) ◽  
pp. 493-498 ◽  
Author(s):  
Ana P. Kiess ◽  
Nishant Agrawal ◽  
James D. Brierley ◽  
Umamaheswar Duvvuri ◽  
Robert L. Ferris ◽  
...  

2008 ◽  
Vol 26 (15_suppl) ◽  
pp. 6061-6061
Author(s):  
G. A. Payne ◽  
G. W. Warren ◽  
J. Valentino ◽  
T. J. Gal ◽  
S. M. Arnold ◽  
...  

2021 ◽  
Author(s):  
Andries H. Groen ◽  
Deborah van Dijk ◽  
Wim Sluiter ◽  
Thera P Links ◽  
Hendrik P. Bijl ◽  
...  

Background: The role of postoperative external beam radiotherapy (EBRT) in patients with residual iodine refractory differentiated thyroid cancer (IR-DTC) is still inconclusive. The aim of this retrospective study was to evaluate locoregional control (LRC) and overall survival (OS), and potential side effects after postoperative EBRT for both microscopic and macroscopic non-radically resected locally advanced IR-DTC. Methods: Between 1990 and 2016, 49 patients with locally advanced IR-DTC received EBRT for microscopic (R1; n=28) or macroscopic (R2; n=21) locoregional residual disease. For more insight into the added effect of EBRT we performed an intra-patient sub-analysis in 32 patients who had undergone more than one surgical intervention, comparing LRC after primary, curative-intended surgery with LRC after repeated surgery plus EBRT. To estimate LRC and OS we used Kaplan Meier curves. From 2007 onwards, we prospectively recorded toxicity data in our head and neck cancer database (n=10). Results: LRC rates five years after EBRT were higher for R1 (84.3%) than for R2 (44.9%) residual disease (p=0.016). The five-year OS rate after EBRT was 72.1% for R1 and 33.1% for R2 disease (p=0.003). In the intra-patient analysis (n=32) LRC rates were 6.3% five years after only initial surgery, and 77.9% after repeated surgery with EBRT (p=<0.001). Acute toxicity was limited to grade I and II xerostomia, mucositis, and hoarseness; only one patient developed late grade III dysphagia. Conclusions: Postoperative EBRT is associated with long-lasting locoregional control and overall survival with acceptable toxicity in patients with locally advanced IR-DTC, especially in microscopic residual disease.


Author(s):  
Judit A. Adam ◽  
Hester Arkies ◽  
Karel Hinnen ◽  
Lukas J. Stalpers ◽  
Jan H. van Waesberghe ◽  
...  

2018 ◽  
Vol 64 (1) ◽  
pp. 79-83
Author(s):  
Vladimir Solodkiy ◽  
Andrey Pavlov ◽  
Aleksey Tsybulskiy ◽  
Anton Ivashin

Introduction. One of the main problems of modem on-courology is treatment for prostate cancer of intermediate and high risk of progression. Modern radiotherapy in this category of patients has an advantage over surgical methods of treatment. One way to improve the effectiveness of radiotherapy is to escalate the dose in the prostate gland. For this purpose a combination of brachytherapy and remote radiotherapy is used. This combination allows increasing the dose of radiation, thereby providing better local control, reducing complications from neighboring organs. Purpose of the study. To conduct a comparative analysis of efficacy and safety of radical treatment of patients with prostate cancer at medium and high risk of progression using a combination of high and low dose rate brachytherapy with external beam radiotherapy. Materials and methods. 107 patients with prostate cancer of the group of medium and high risk of progression combined treatment (brachytherapy with external beam radiotherapy) was conducted. 53 patients underwent combined treatment (HDR-brachytherapy and external beam radiotherapy). 54 patients underwent combined treatment (LDR-brachytherapy and external beam radiotherapy). The observation period was 5 years. Conclusion. In a comparative analysis in groups of combined radiotherapy with the use of high-dose and low-dose-rate brachytherapy, the same effectiveness of immediate and long-term results of treatment was demonstrated. A significant reduction in early and late toxic reactions in patients with high-power brachytherapy has been demonstrated.


Sign in / Sign up

Export Citation Format

Share Document